title: [Urotoxicity of enocitabine (BH-AC) and aclarubicin (ACM) in pediatric patients with hematological malignancies].
authors.forename: F
authors.initials: F
authors.lastname: Fujiwara
authors.forename: T
authors.initials: T
authors.lastname: Yoshihara
authors.forename: S
authors.initials: S
authors.lastname: Ikushima
authors.forename: N
authors.initials: N
authors.lastname: Esumi
authors.forename: S
authors.initials: S
authors.lastname: Todo
authors.forename: Y
authors.initials: Y
authors.lastname: Morioka
authors.forename: S
authors.initials: S
authors.lastname: Imashuku
authors.forename: S
authors.initials: S
authors.lastname: Okano
authors.forename: T
authors.initials: T
authors.lastname: Hashida
authors.forename: T
authors.initials: T
authors.lastname: Ishii
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage / Q000009:adverse effects; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006417:Hematuria / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D015337:Multicenter Studies as Topic; D012189:Retrospective Studies
chemical_list: D003561:Cytarabine; D015250:Aclarubicin; C015019:enocitabine